MedTrace Logo

ICP-332 in Subjects With Non-segmental Vitiligo

NCT07047612 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 603

Last updated 2025-08-07

No results posted yet for this study

Summary

This a phase II/III randomized, double-blind, placebo-controlled, parallel group, adaptive design, multi-center study to evaluate the efficacy and safety of ICP-332 in subjects with non-segmental vitiligo。The study consisted an phase 2 part and an phase 3 part.

Conditions

  • Non Segmental Vitiligo

Interventions

DRUG

ICP-332 Tablets

ICP-332 will be administered as tablet

DRUG

ICP-332 Placebo Tablets

ICP-332 Placebo will be administered as tablet

Sponsors & Collaborators

  • Beijing InnoCare Pharma Tech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-09
Primary Completion
2029-04-30
Completion
2029-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07047612 on ClinicalTrials.gov